Attentive Therapeutics

11:30 AM - 11:45 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Attentive Therapeutics is developing ATT-377 which combines a proven ADHD medication with an appetite protectant. ADHD is the most prevalent psychiatric disorder in children and until now, there has been no way to address the common appetite and weight suppression which limit current treatment with otherwise effective stimulants.

We have recently successfully completed a prospective, double-blinded, placebo-controlled, dose-ranging clinical trial for ATT-377 which demonstrated a highly significant impact on weight while maintaining the high efficacy of stimulants on ADHD.

Attentive Therapeutics has two patent families covering methods of use/treatment and composition of a single capsule. IP has issued and is pending.

The company is looking to fund further development through licensing or additional funding.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2012
Main Therapeutic Focus:
Lead Product in Development:
ATT-377
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1